ASX - Delayed Quote AUD

Opthea Limited (OPT.AX)

Compare
0.6450 -0.0250 (-3.73%)
At close: 4:10:32 PM GMT+11

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Dr. Frederic Guerard M.S., Pharm.D. Chief Executive Officer 1.14M -- 1972
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. Founder & Chief Innovation Officer 887.18k -- 1974
Ms. Karen Adams CPA VP of Finance & Company Secretary 448.43k -- 1971
Mr. Thomas Charles Reilly Chief Financial Officer -- -- 1972
Mr. Kevin Bitter VP of Strategy & Corporate Development -- -- 1992
Mr. Anand Sundaram Vice President Marketing -- -- --
Dr. Fang Li Ph.D. Senior Vice President of Regulatory Affairs -- -- 1964
Dr. Julie Clark M.D., M.S. Senior Vice President of Clinical Development -- -- 1975
Dr. Arshad M. Khanani M.A., M.D. Chief Medical Advisor & Chairman of Medical Advisory Board -- -- --
Ms. Jen Watts VP Global Clinical Operations -- -- --

Opthea Limited

650 Chapel Street
Suite 0403, Level 4
South Yarra, VIC 3141
Australia
61 3 9826 0399 https://opthea.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
33

Description

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.

Corporate Governance

Opthea Limited’s ISS Governance QualityScore as of December 1, 2024 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 10; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 26, 2025 at 10:59 AM UTC - March 3, 2025 at 12:00 PM UTC

Opthea Limited Earnings Date

Recent Events

October 11, 2004 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers